Industry Satellite Symposia

The American Society for Radiation Oncology (ASTRO) has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposium. The symposia constitute the content and views of the provider and are not part of the official ASTRO Annual Meeting program.

Sunday, September 27, 2026

6:30 p.m. - 8:00 p.m.: Dinner and Hybrid Symposium

Cases and Conversations – Evolving Radiation Strategies in HER2-Positive Breast Cancer: Early-Stage Through Metastatic Disease

Location: Westin Boston Seaport District
Harbor Ballroom I
425 Summer Street
Boston, MA 02210

CME Credits: Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™ and 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This educational activity is directed toward ASTRO congress attendees, including an audience of radiation oncologists, medical and surgical oncologists, advanced practice providers, nurses, and other healthcare professionals managing HER2-positive breast cancer.

Learning Objectives: Upon completion, learners will be better able to:

• Evaluate the safety profile of concurrent and sequential radiation therapy with T-DXd, including strategies to distinguish drug-related ILD from radiation pneumonitis.
• Develop a radiation treatment plan that accounts for the overlapping pulmonary and cardiac toxicity risks of ADC-based systemic therapy in HER2-positive breast cancer.
• Assess the implications of recent and emerging clinical trial data for the role of radiation therapy in early-stage and metastatic HER2-positive breast cancer.
• Apply a multidisciplinary framework to integrate systemic and local therapy for HER2-positive breast cancer with brain metastases.

This activity is supported through educational grants from AstraZeneca Pharmaceuticals LP, and Daiichi Sankyo, Inc.